VERX Stock Recent News

The Investment Committee give you their top names to watch for the second half.

KING OF PRUSSIA, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a global provider of tax technology solutions, today announced that David DeStefano, Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at the 20th Annual Needham Technology, Media, & Consumer Conference.

Vertex, Inc. (NASDAQ:VERX ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Joe Crivelli - Vice President of Investor Relations David DeStefano - President and Chief Executive Officer John Schwab - Chief Financial Officer Conference Call Participants Joshua Reilly - Needham & Company, LLC Christopher Quintero - Morgan Stanley Adam Hotchkiss - Goldman Sachs George Cruz - Citigroup Inc. Jake Roberge - William Blair & Company Kyle Aberasturi - BMO Capital Markets Alexander Sklar - Raymond James Financial, Inc. William Jellison - D.A. Davidson & Co. Rob Oliver - Robert W.

The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.15 per share a year ago.

KING OF PRUSSIA, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its first quarter ended March 31, 2025.

Vertex Pharmaceuticals' (VRTX -9.39%) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date.

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain management portfolio. The FDA approval of Journavx marks the beginning of a new era for the company. VRTX is not going to be the same company by 2030. I expect notable changes in its margin profile as the company diversifies into new markets.

On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings.

The company discloses narrower-than-expected access to its new painkiller.